- All
- Anesthesiology
- Anti-infectives and immunology
- Biologicals
- Blood disorders
- Cardiovascular
- CNS
- Diabetes
- Endocrinology/Sexual health
- Gastrointestinal Diseases
- General modelling
- Lung Diseases
- Methods
- Oncology
- Paediatrics
- Pain
- Peripheral Nervous System
- Safety pharmacology
Willmann S., Ince I, Ahsman M., Coboeken K., Zhang Y., Thelen K., Kubitza D., Zannikos P., Zhou W., Pina L., Post T., Lippert J. Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients with congenital heart disease aged 9 years and above. CPT: pharmacometrics & systems pharmacology, p001-011, 2022. [Link to publication].
Muliaditan M, Sepp A. Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies. Clin Transl Sci. 2022. [Link to publication]
Fu Y., Taghvafard H., Said M.M., Rossman E.I., Collins T.A., Billiald-Desquand S., Leishman D., Graaf van der P.H., Hasselt van C.J.G., Snelder N. A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables. CPT Pharmacometrics Syst Pharmacol. 2022;00:1–13. [Link to publication].
Engbers A.G.J., Völler S., Flint R.B., Goulooze S.C., de Klerk J., Krekels E.H.J., van Dijk M., Willemsen S.P., Reiss I.K.M., Knibbe C.A.J., Simons S.H.P. The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants. Clin Pharmacol Ther. 2022 [Link to publication]
Goulooze S.C., Heerspink H.J.L., van Noort M., Snelder N., Brinker M., Lippert J. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. T. Clin Pharmacokinet. 61, 451–462. 2022 [Link to publication].
Bosch R., Petrone M., Arends R., Vicini P., Sijbrands E.J.G., Hoefman S., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT Pharmacometrics Syst Pharmacol, 2021. [Link to publication]
Willmann S., Marostica E., Snelder N., Solms A., Jensen M., Lobmeyer M., Lensing A. W. A., Bethune C., Morgan E., Yu R. Z., Wang Y., Jung S. W., Geary R., Bhanot S. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacometrics Syst. Pharmacol. 10(8): 890–901, 2021. [Link to publication]
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. Clin Pharmacokinet. 2021. . [Link to publication]
Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clin Pharmacokinet. 2021. [Link to publication]
Willmann S., Coboeken K., Zhang Y, Mayer H., Ince I, Mesic E., Thelen K., Kubitza D., Lensing A.W.A., Yang H., Zhu P., Mück W., Drenth H., Lippert J. Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions. CPT Pharmacometrics Syst Pharmacol. 2021 Jul 22. doi: 10.1002/psp4.12688 . [Link to publication]
DeJongh J., Ahsman M., Snelder N. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy. J. Pharmacokinet. Pharmacodyn. 7 2021 [Link to publication].
Berg van der P, Gao W, Ahsman M.J, Arrington L, Kesisoglou F, Miller R, Post T.M, Rizk M.L. Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development. CPT Pharmacometrics Syst Pharmacol. 2021 May 2. doi: 10.1002/psp4.12644. Epub ahead of print. PMID: 33934558. . [Link to publication]
Bukkems V. E., Post T. M., Colbers A. P., Burger D. M., Svensson E. M. A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200mg in pregnant women living with HIV. CPT Pharmacometrics Syst. Pharmacol.(December 2020): 1–12, 2020. [Link to publication]
Solms A., Shah A., Berntorp E., Tiede A., Iorio A., Linardi C., Ahsman M., Mancuso M. E., Zhivkov T., Lissitchkov T. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann. Hematol. 99(11): 2689–2698, 2020 [Link to publication].
Snelder N., Heinig R., Drenth H.J., Joseph A., Kolkhof P., Lippert J., Garmann D., Ploeger B., Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 59(3), 359-370. 2020 [Link to publication]